This article is more than 5 years old. Information may no longer be current.

FDA Approves Polyethylene Glycol 3350 Powder for Oral Solution to Treat Occasional Constipation

Issue: February 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ANI Pharmaceuticals announced the FDA has approved its abbreviated new drug application for polyethylene glycol 3350 powder for oral solution, 17 mg/scoopful, for the treatment of occasional constipation.

“We are pleased to have received FDA approval of our [abbreviated new drug application] for polyethylene glycol 3350 powder for oral solution, bringing our total internal and partnered [abbreviated new drug application] approvals for 2015 to three,” Arthur S. Przybyl, president and CEO of ANI Pharmaceuticals, said in a press release.

IMS Health reports the product’s trailing 12-month sales are $13.5 million, according to the press release.